Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1270–1274. doi: 10.1038/bjc.1995.245

Volunteers or victims: patients' views of randomised cancer clinical trials.

M Slevin 1, J Mossman 1, A Bowling 1, R Leonard 1, W Steward 1, P Harper 1, M McIllmurray 1, N Thatcher 1
PMCID: PMC2033847  PMID: 7779722

Abstract

Randomised clinical trials are essential for the objective evaluation of different treatment strategies in cancer. However, in the field of oncology, very few of the eligible patients are entered into trials, and most treatments have only been tested on a small percentage of patients. For doctors, a major deterrent to participating in trials is the lack of resources--particularly time, but often also the local facilities. This report suggests that patients themselves are willing to take part in clinical research, and are attracted by being treated by a doctor with a specialist interest in the disease and encouraged by the possibility that their progress will be monitored closely. With the recent NHS changes, it is timely for the Department of Health and other national health departments to consider carefully what can be done to ensure that no new treatments are adopted without effective evaluation. This will require departments of health to identify and implement ways to facilitate accrual of appropriate numbers of patients onto research protocols (whether non-randomised phase I or phase II studies or large, multicentre phase III trials) over short time periods.

Full text

PDF
1270

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angell M. Patients' preferences in randomized clinical trials. N Engl J Med. 1984 May 24;310(21):1385–1387. doi: 10.1056/NEJM198405243102111. [DOI] [PubMed] [Google Scholar]
  2. Antman K., Amato D., Wood W., Carson J., Suit H., Proppe K., Carey R., Greenberger J., Wilson R., Frei E., 3rd Selection bias in clinical trials. J Clin Oncol. 1985 Aug;3(8):1142–1147. doi: 10.1200/JCO.1985.3.8.1142. [DOI] [PubMed] [Google Scholar]
  3. Baum M. New approach for recruitment into randomised controlled trials. Lancet. 1993 Mar 27;341(8848):812–813. doi: 10.1016/0140-6736(93)90573-y. [DOI] [PubMed] [Google Scholar]
  4. Cassileth B. R., Zupkis R. V., Sutton-Smith K., March V. Informed consent -- why are its goals imperfectly realized? N Engl J Med. 1980 Apr 17;302(16):896–900. doi: 10.1056/NEJM198004173021605. [DOI] [PubMed] [Google Scholar]
  5. Davis S., Wright P. W., Schulman S. F., Hill L. D., Pinkham R. D., Johnson L. P., Jones T. W., Kellogg H. B., Jr, Radke H. M., Sikkema W. W. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer. 1985 Oct 1;56(7):1710–1718. doi: 10.1002/1097-0142(19851001)56:7<1710::aid-cncr2820560741>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  6. Friedman M. A., Cain D. F. National Cancer Institute sponsored cooperative clinical trials. Cancer. 1990 May 15;65(10 Suppl):2376–2382. doi: 10.1002/1097-0142(19900515)65:10+<2376::aid-cncr2820651504>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  7. Gotay C. C. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991;33(5):569–577. doi: 10.1016/0277-9536(91)90214-w. [DOI] [PubMed] [Google Scholar]
  8. Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mackillop W. J., Palmer M. J., O'Sullivan B., Ward G. K., Steele R., Dotsikas G. Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer. 1989 Mar;59(3):388–395. doi: 10.1038/bjc.1989.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Penman D. T., Holland J. C., Bahna G. F., Morrow G., Schmale A. H., Derogatis L. R., Carnrike C. L., Jr, Cherry R. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol. 1984 Jul;2(7):849–855. doi: 10.1200/JCO.1984.2.7.849. [DOI] [PubMed] [Google Scholar]
  11. Simes R. J., Tattersall M. H., Coates A. S., Raghavan D., Solomon H. J., Smartt H. Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) 1986 Oct 25;293(6554):1065–1068. doi: 10.1136/bmj.293.6554.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Smyth J. F., Mossman J., Hall R., Hepburn S., Pinkerton R., Richards M., Thatcher N., Box J. Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ. 1994 Aug 13;309(6952):457–461. doi: 10.1136/bmj.309.6952.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tannock I. F. Some problems related to the design and analysis of clinical trials. Int J Radiat Oncol Biol Phys. 1992;22(5):881–885. doi: 10.1016/0360-3016(92)90783-e. [DOI] [PubMed] [Google Scholar]
  14. Taylor K. M., Margolese R. G., Soskolne C. L. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 1984 May 24;310(21):1363–1367. doi: 10.1056/NEJM198405243102106. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES